We are a global bioscience company dedicated to healthy aging.

The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. NAD+ levels in humans have been shown to decline with age, among other factors, and may be increased through supplementation with NAD+ precursors. ChromaDex is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen®. Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex’s patent portfolio.

The Company delivers Niagen® as the sole active ingredient in its consumer product Tru Niagen® available at www.truniagen.com and through partnerships with global retailers and distributors. The Company also develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The Company further offers natural product fine chemicals, known as phytochemicals, and related research and development services.

Key Investment Highlights:

  • Leader in the rapidly growing NAD+ market for healthy aging
  • Large addressable market - $170B global TAM in vitamins and supplements (+5% growth annually)
  • Opportunity to capture share of broader healthy aging end-markets e.g. aesthetics and performance nutrition
  • Proven and proprietary NAD+ boosting supplement (Tru Niagen®) $60+ million in sales in 2022 (+62% CAGR (1) )
  • Strategic partnerships to grow Tru Niagen® global distribution footprint with focus on Asia Pacific region
  • Independent scientific research supporting benefits of proprietary ingredient with 20+ clinical trials
  • Significant opportunity driven by expanded benefit claims, including therapeutic potential in pharmaceutical field
  • Strong intellectual property portfolio with 60+ patents for Niagen® and other NAD precursors
  • Strengthening financial position evidenced by delivering cash flow break-even in Q4 2022
(1) CAGR calculated for the 2017-2022 calendar years period

Build a Global Brand

In March 2017 ChromaDex began a strategic shift from an ingredient and testing company with the long-term goal of building its new consumer product, TRU NIAGEN®, into a global brand. The company has since expanded retail distribution into four new international markets and has signed supply agreements with strong global partners, including Nestlé Health Science and A.S. Watson Group. (See link to Nestlé Health Science press release) and (See link to latest A.S. Watson Group press release)

Own the Science

As a leader in the growing field of NR and NAD research, ChromaDex continues to build upon and protect its intellectual property, invest in quality research, partner with the world's leading scientists, and educate consumers on the health benefits of NR. (Notable Scientific Research) (Patent Portfolio)

ChromaDex has a strong patent portfolio around TRU NIAGEN®, with over 16 licensed global patents or patents pending. The lead patent is one that is exclusively licensed from Dartmouth. In September 2018, ChromaDex and the Trustees of Dartmouth College filed a patent infringement complaint in the United States District Court for the District of Delaware against Elysium Health, Inc. (“Elysium”). The complaint alleges that Elysium’s BASIS® dietary supplement violates patents that cover compositions containing isolated nicotinamide riboside (“NR”) held by Dartmouth and licensed exclusively to ChromaDex. (See link to Elysium related litigation)

Focus on Fundamentals

ChromaDex is committed to being a fundamentally sound, principled business operation focused on the long-term. The company continues to build a world class team with greater depth in brand reputation, communications, science, regulatory and sales.

ChromaDex recently secured regulatory approvals from the EU and Australia, which includes five-, and two-year exclusivity, respectively. This continues an unprecedented streak of successful regulatory acceptance of NR, a key point of differentiation from any other novel NAD precursors.

It is the company’s mission to lead by example in this industry. ChromaDex Co-Founder and Chairman, Frank Jaksch, is a Board Member of the Natural Products Association, and ChromaDex Chief Executive Officer, Rob Fried, is a Board Member of the Council for Responsible Nutrition.

For more than 20 years, and through a transition from an ingredients business to a direct-to-consumer dietary supplements company, we have remained true to our commitment to innovation, science and safety.

See What's New...

Latest News

Latest Annual Filings

Latest Quarterly Results

Latest Presentation